India’s Ayu Life Sciences is investing AED 33 million (approximately $9 million) to establish a state-of-the-art manufacturing facility in Dubai’s Jebel Ali Free Zone (Jafza), marking a significant expansion into the Middle East’s healthcare sector.
The 13,500-square-meter facility will specialize in producing next-generation wound care solutions and surgical treatments, addressing the growing global demand for high-quality, sustainable healthcare products. Key products to be manufactured include:
- Velgraft™: An artificial skin substitute designed for scar-free healing and tissue regeneration.
- Velvert™: A natural antimicrobial wound care dressing formulated to accelerate healing and prevent infections.
- VelNez™: A nasal and ear dressing that enhances patient comfort and post-surgical recovery.
These products are backed by a portfolio of 22 global patents and developed using eco-friendly materials and natural components to minimize environmental impact. The facility’s development will occur in two phases, with Phase 1 expected to be operational by late 2025 and full completion by 2027.
Dr. Rajan Datt, Managing Director of Ayu Life Sciences, expressed enthusiasm about the expansion, “We’re excited to announce our new facility in Jafza, marking a major milestone for Ayu Life Sciences.
“Our commitment to proprietary research and development enables us to consistently deliver excellent wound care products so we can continually push the boundaries of patient care.
“We look forward to breaking ground on this new facility and extending the reach of our flagship products like Velgraft™, Velvert™, and VelNez™ to more patients in the Middle East and around the globe.”
Ayu Life Sciences: Strengthening Dubai’s Position in Global Healthcare Manufacturing
Jafza’s strategic location and robust infrastructure make it an ideal hub for Ayu Life Sciences’ expansion. The free zone is already home to over 800 manufacturing companies from 75 countries, fostering a thriving ecosystem of global innovators.
Abdulla Al Hashmi, Chief Operating Officer Parks & Zones, DP World GCC, highlighted the significance of this development, “Jafza’s manufacturing infrastructure and strategic connectivity make it the ideal launchpad for innovators like Ayu Life Sciences.
“This facility reinforces Dubai’s growing role as a global hub for the healthcare and advanced medical manufacturing sectors. As we continue to grow, we remain committed to supporting cutting-edge industries that drive economic growth and improve lives.”
The launch coincides with a surge in demand for artificial skin, with the market projected to grow from $3.1 billion in 2024 to $5.3 billion by 2032. Ayu Life Sciences currently exports from its Delhi facility to over 20 markets across North America, Europe, Asia, Australia, Africa, and the Middle East, many with highly regulated healthcare markets.
In addition to advanced wound care, the company is progressing in the field of regenerative medicine. Clinical trials are underway for a novel therapy using cells similar to those in the pancreas to regulate blood sugar for patients with Type 1 diabetes, and for Velnerve™, a solution for peripheral nerve injuries.
This strategic investment not only enhances Ayu Life Sciences’ global footprint but also aligns with Dubai’s vision to become a leading hub for healthcare innovation and advanced medical manufacturing.
